Back to Search
Start Over
Fentanyl citrate sublingual formulation (Vellofent®) for quick BTcP hindering.
- Source :
-
Minerva medica [Minerva Med] 2016 Apr; Vol. 107 (2), pp. 114-22. - Publication Year :
- 2016
-
Abstract
- The management of cancer pain presents manifold challenges: even though background pain is adequately controlled, patients frequently experience episodes of acute pain exacerbation known as breakthrough cancer pain (BTcP). The characteristics of BTcP are a rapid onset, a short duration, and a severe intensity. An innovative sublingual fentanyl citrate formulation (Vellofent®) has been developed to target BTcP. The new formulation allows to increase the solubility of fentanyl and to provide optimal oromucosal conditions for rapid drug absorption, thus featuring a shorter time to onset of pain relief (from 6 minutes post-administration).
Details
- Language :
- English
- ISSN :
- 1827-1669
- Volume :
- 107
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- Minerva medica
- Publication Type :
- Academic Journal
- Accession number :
- 27064584